Podcasts about newsletterto

Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.In today's episode I'm joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two decades advancing cancer care, from clinical practice to leadership roles shaping strategy across Europe and Canada. Since joining Daiichi Sankyo in 2021, he has been at the forefront of one of the industry's most ambitious ADC pipelines, overseeing more than 60 clinical trials across 24 countries and driving landmark approvals that are redefining treatment in breast, lung, and gastric cancers.This week's episode is brought to you with the support of Kadans. Looking for the perfect space to grow your Life Sciences company? Kadans Science Partner is Europe's leading provider of cutting-edge lab and offices spaces, tailored to your needs. Kadans puts you at the centre of innovation, giving you the chance to connect with top researchers, universities, and investors through its international network. Here, you'll join a vibrant community of innovators driving real change. Are you ready to take your research to the next level? Learn more at kadans.com – where innovation thrives. 01:45.         Meet Markus Kosch03:12.         Clinical background shaping an industry role04:46.         Daiichi Sankyo's 40-year oncology legacy06:19.         European investments and Munich hub10:34.         ADC platform strengths explained14:20.         Key ESMO 2025 trial dataClarification: The reference to ‘TB01' at 16:24 refers to the TROPION-Breast02 clinical trial, not TB01.19:43.         Managing risks and partnerships23:35.         Patient advocacy in trial design33:59.         Future of oncology and ADCsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 oncology deals in 2025 spotlight where industry leaders are betting bigAstraZeneca and Daiichi Sankyo's Enhertu recommended for approvalTen drugs to watch in 2025: will these therapies become blockbusters?

Send us a textDee and Carol talk about flowers and veggies with 'viridis' as the species name, plus a book on houseplant propagation, and more.For all the details, check out our newsletterTo watch this episode on YouTube: click hereInsect of the Week: Paper WaspsFlowers:Ephedra viridis - Morman Tea Helleborus viridis - Green HelleboreAsclepias viridis - Green Milkweed Crataegus viridis - Green HawthornAcer palmatum ‘Viridis.'Vegetables:Collard Greens - Brassica oleracea var. viridis Callaloo - Amaranthus viridisCucumber Viridis F1 On the Bookshelf:The Ultimate Guide to Houseplant Propagation: Step-by-step techniques for making more houseplants… for free! By Lindsay Sisti from @alltheplantbabies on Instagram (Amazon Link)Dirt:Why do ginkgo trees lose their leaves all at once? On InstagramRabbit Holes:Dee: Where does rose oil come from? An article, an Instagram link, and an article about how it's used!Carol: The Unselected Journals of Emma M. Lion, Volume 3 by Beth Brower, and The Killer Question by Janice Hallett. Check out our affiliate links here.Support the showOn Instagram: Carol: Indygardener, Dee: RedDirtRamblings, Our podcast: TheGardenangelists.On Facebook: The Gardenangelists' Garden Club.On YouTube.

Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it's a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the right company at just the right time. Get it right, and you walk away with a clear path forward and the cash to fund it. But get unlucky and you might find yourself with few options in the New Year.This year, we decided to follow one biotech heading into their first BIO-Europe partnering conference. We met with DISCO Pharma three times over the last month to follow their BIO-Europe journey:Before the event to learn about the science behind DISCO and understand what their goals were heading into BIO-Europe. At the event itself to talk about how the partnering meetings had been going and how the event had shaped up for DISCO. A week after BIO-Europe had closed, diving into the follow-up activities and learning about the next steps for this German biotech.I hope you enjoy my conversations with Ajla Hrle, Chief Business Officer at DISCO, and this behind the scenes look at BIO-Europe from an innovator's perspective.02:25          Preparing for BIO-Europe16:51           On the floor at BIO-Europe22:23          Following up from BIO-EuropeInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: BIO-Europe partnering: Australian biotech companies share their experiencesPractical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepBiotech in Vienna: a budding life science hub 

Last week saw more than 5,900 people from 3,200 companies gather in Vienna, Austria, for the continent's largest biopharma partnering conference, BIO-Europe. Over three days the world's top pharma companies, most innovative biotechs, and life science professionals from 60 countries took more than 32,000 one-on-one meetings, made the connections, and sealed deals that will drive the industry forward into 2026 and beyond.Among the highlights of BIO-Europe this year was the Startup Spotlight contest. This exciting competition offers biotech entrepreneurs an affordable opportunity to engage with top-tier investors and other important players in the biotech industry and to take their business to the next level. Eight finalists made their pitches at BIO Europe and one, Fusix Biotech from Germany, came out on top.This week on Beyond Biotech I'm joined by Fusix Biotech's Managing Director and co-founder, Jennifer Altomonte, who tells me about her journey through the industry, Fusix's InFUSE platform, and what it's like to pitch – and win – one of the most important biopharma startup competitions of the year.01:34               Meet Jennifer Altomonte05:12               Co-founding Fusix Biotech10:37               Fusix Biotech and the InFUSE platform18:50               Intellectual property for a young company20:04               The BIO-Europe Startup Spotlight23:47               The impact of the competition win29:05               The milestones ahead30:33               What does a successful 2026 look like for Fusix Biotech?31:56               Learn more about Fusix BiotechThis episode is supported by EBD Group.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: BIO-Europe partnering: Australian biotech companies share their experiencesFour New Technologies That Will Change Cancer TreatmentWhy is the immunology and inflammation market suddenly attracting a wave of investment?

Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern's Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens in just 35 minutes, no lab required.In this episode I'm joined by Emma Hayhurst who shares her journey into diagnostics, Llusern's mission, and the emergence of Wales as a biotech hub with a growing life sciences sector fueling local innovation. We discuss UTI prevalence, diagnostic gaps, and how rapid, accurate testing can transform patient care and antimicrobial stewardship. 02:14               Meet Emma Hayhurst04:37               Introducing Llusern Scientific07:21               Collaboration between Llusern and the academy08:50               The life science ecosystem in Wales12:10               Urinary tract infections (UTIs)15:45               UTI patient demographics16:54               Health impacts of UTIs: sepsis, antibiotic resistance, and more19:01               Existing UTI diagnostic options and their shortcomings24:41               Llusern's Lodestar DX29:03               A point-of-care test, not a lab test31:44               Applications beyond UTIs36:03               Looking forward at LlusernInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Life sciences in Wales: biotechs in the scene in 2025Fighting Antimicrobial Resistance with Fast Molecular DiagnosticsUltra-Fast Diagnostics Could Transform Sexual Health

Today, I'm joined by Héctor García Martín, a Staff Scientist at Lawrence Berkeley National Laboratory. A pioneer in metabolic engineering and computational biology, Héctor has spent over a decade decoding microbial systems, everything from termite guts to genome-scale flux models, to unlock sustainable biomanufacturing.Now, he's leading the charge in self-driving labs: AI-powered, robotic systems that automate experiments, predict biological behavior, and accelerate the design of microbes that produce fuels, medicines, and materials.In this episode, we'll dive into why biology has traditionally proven so hard to engineer, how AI and robotics are changing that, and where this revolution is headed next. I hope you enjoy my discussion with Hector Garcia Martin.01:12              Meet Hector Garcia Martin12:47              Introduction to the Berkeley National Laboratory14:42              Challenges in synthetic biology17:21              How unpredictability complicates biomanufacturing19:30              Self-driving labs at the nexus of AI, robotics, and biomanufacturing22:23               How is AI integrated into optimize enzyme expression28:01               Where is the market for self-driving labs?28:47               The future of synthetic biology32:24               The most exciting trends in AI-driven biomanufacturing34:10               The expected impacts of self-driving labs on everyday life35:28               Advice for aspiring scientistsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Synthetic Biology @ LabiotechEuropean biotech: trends to watch in 2025The coming of age of European synthetic biology

Today we're diving into the world of expression systems with Iskandar Dib, of Validogen and we'll explore the remarkable potential of Pichia pastoris, a methylotrophic yeast that's revolutionizing pharmaceutical protein production and beyond. From industrial enzymes to biomaterials, food, feed, and diagnostics, Pichia offers a reliable, scalable, and cost-efficient platform for recombinant protein expression. Iskandar explains how biotechs can unlock Pichia's full potential through Validogen's sophisticated tools and strategies, fine-tuning protein expression with innovative genetic approaches and robust screening systems to deliver unmatched yields and quality. 01:06               Why Pichia is often overlooked or underestimated03:29               The basics of Pichia pastoris05:25               How Pichia compares to microbial hosts like E.coli08:14               Key advantages over mammalian cell systems10:21               Pichia as a system for secreted production11:30               Pichia and post-translational modifications14:30               The challenges of working with Pichia16:25               Strain optimization and genetic engineering17:29               Meet Iskandar Dib and Validogen19:03               The UNLOCK PICHIA platform24:00               Real-world applications of Pichia pastoris in biopharma27:19               When Pichia outperforms expectations28:25               Adapting Pichia for emerging fields30:23               Advice for those considering Pichia pastoris for protein expression33:23               Learn more about ValidogenThis episode is sponsored by Validogen.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Pichia case studiesUnlocking Pichia for industry

In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles, executing more than 165 transactions that have fueled breakthroughs in life sciences.In this interview we examine the evolution of alternative funding models, the transformative impact of alternative funding models on biotech innovation, partnerships, and M&A, and take a macro view on the financial health of the industry amid economic shifts. 02:10               Meet Clarke Futch07:58               HCRx and its mission18:55               Differences between a royalty firm and a venture firm21:34               Alternative funding models in biotech24:49               Are VCs pulling back? Are alternatives rising?30:20               How royalty financing impacts partnerships and M&A33:02               Do alternative financing models risk stifling innovation?36:33               A macro look at the health of the biotech sector41:33               What areas of biotech are underfunded right now?46:22               Looking forward: the 6-12 months ahead?48:10               Advice for founders navigating financial uncertaintyInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Moving with the times: biopharma royalty deals on the riseThe ABC of biotech startup funding2025 biotech deals tracker

When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female condom in 1993. For men, however, there has been little advancement since the invention of the rubber condom in 1855 and the first vasectomies in humans around the turn of the 20th century.Contraline is a biotechnology company that is aiming to change that record. They are currently heading into Phase II trials with a therapy that they claim is reliable, long lasting, easy to use, and reversible. This week, I talk with Kevin Eisenfrats, CEO of Contraline, about the challenges of bringing a new contraceptive to market, how to manage clinical trials on multiple continents, and what the world might look like if the contraceptive burden passes from women to men.01:21                      Kevin Eisenfrats and Contraline07:28                      Contraline's ADAM09:09                      How ADAM works11:39                      Reversibility is a differentiator for ADAM14:01                      Hormonal gels and contraception17:14                      The phase I trial in Australia21:47                      The implantation process25:07                      Moving into phase II27:04                      The male contraception market29:30                      Fundraising for male contraception33:06                      The gendered burden of contraception34:54                      The future of male contraception36:49                      The cultural and social impact of male contraceptionInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: MedinCell Granted €17M to Develop Cheap Long-Acting ContraceptionInpart Connect: Reversible Male ContraceptiveInpart Connect: Cyclic Peptides as Non-hormonal Male Contraceptive Agents and Methods of Use ThereofInpart Connect: Noninvasive Laser Vasectomy

Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I'm interested' to ‘I'm signing on the dotted line'?This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical steps that biotechs need to take to move from a series A to a series B, the key members of the team that pulled the deal together, how to keep existing investors engaged while bringing new money on-board, and how it feels when it is all done. 01:14               Meet Gerard Caelles04:34               The Splice Bio platform12:34               Raising $135 million in uncertain times15:31               Laying the groundwork for a series B18:15               Building a fundraising team20:45               Identifying and approaching new investors22:38               Fundraising challenges in 202526:37               Refining the strategy and pitch29:00               Choosing lead investors 31:59               Keeping existing investors on board34:12               A look behind the scenes 37:52               What's next for Splice Bio42:10               Learn more about Splice BioInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Labiotech's 2025 Biotech Funding TrackerThe ABC of biotech startup fundingBudget blues: where are cell and gene therapies heading? 

Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering from autoimmune, gastrointestinal, and metabolic disease. For top pharma companies, identifying these innovations early is essential and, for university labs, spinouts and startups, getting their science in front of the right industry partners is key. So how does science meet industry, and how can top pharma and venture investors find the next blockbuster?This week I sat down with Joseph Ferner of Inpart, the author of a new R&D Trends Report on Immunology and Inflammation. He explained the shape of the research landscape, the areas that are generating the most interest amongst industry and investors, and the ways in which digital platforms are helping innovative scientists connect with those who have the experience and finance to bring their technologies and therapies to market.Download the Immunology & Inflammation R&D Trends ReportCreate a free Inpart Connect accountSpeak with the Inpart team02:18               The 2025 Immunology and Inflammation R&D Trends Report08:30               Priorities and challenges in immunology and inflammation research10:18               The impact of immune system complexity on drug development13:12               The challenge of clinical heterogeneity15:33               The role of organoids in immunology and inflammation R&D17:10               Comparing organoid models to animal models19:51               The R&D landscape in 202522:40               Popular modalities in immunology and inflammation research24:45               The top innovations in the 2025 R&D Trends Report28:56               How to score and rank innovations in a rapidly evolving market33:22               Engagement trends between researchers and industry partners37:09               Why companies decline to engage with academic researchers43:36               The Inpart Connect platform and how it works48:49               Looking forward to the next R&D Trends ReportInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Why is the immunology and inflammation market suddenly attracting a wave of investment?

Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it's little wonder that the biggest partnering events attract hundreds of innovators and thousands of attendees.One of the largest industry partnering events in Europe is BIOSPAIN. This year BIOSPAIN will take place in Barcelona, and the Catalan city will welcome participants from more than 40 countries for three days of exhibitions, partnering meetings, and presentations from industry leaders. Labiotech will be on the ground reporting from BIOSPAIN this year, and so we sat down with Stewart Medina fromBIOSPAIN to find out exactly what's in store.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Catalonia: A biotech hub going from strength to strength, with Barcelona at its core10 biotech companies you should know about in Spain20 years of BIOSPAIN – The evolution of an international biotech event

How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these partnerships?These are questions that this week's guest, Mati Gill, CEO of AION Labs in Israel, is perfectly positioned to answer.AION Labs has an innovative company creation process that empowers scientists and startups to tackle high-impact pharma challenges with AI, backed by top-tier data, funding, and expertise from global pharma partners. In the middle of a transformative decade for AI-driven drug discovery, and with Israel poised to play an increasingly significant part, Mati explains how venture studios are helping to foster groundbreaking solutions for global health challenges.01:07               Meet Mati Gill07:19               The biotech industry in Israel09:38               How the Israeli biotech industry is changing with AI and other technologies13:01               The biggest challenges facing Israeli biotechs and biopharma18:07               AION Labs and its mission20:27               AION Building and AION Seeding24:03               Why top pharma wants to partner with AION Labs startups27:53               Workshopping startup ideas with top pharma companies32:04               The future of venture studios like AION Labs36:33               At the intersection of AI, biotech, and Israel's innovation ecosystem39:24               Advice for entrepreneurs and scientistsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: AION Labs launches AI startup to improve drug trialsThe 5 hottest biotech companies making waves in IsraelWhat to look for in a biotech incubator

Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years. They are a leader in both established and emerging technologies and today their 19,000 employees across more than 30 sites on five continents generate annual sales of more than $4.4 billion. We sat down with Alice Harrison, Global Technical Director (CMC and Analytics), and Megan Mason, Global Process Development Implementation Manager, to learn more about how Lonza is helping innovators large and small develop and scale their therapies and deliver better outcomes for patients worldwide._____The information in this podcast is believed to be correct at the time of recording, and is for information only. While we make reasonable efforts to ensure that the content is accurate, we make no representations or warranties of any kind regarding its accuracy, completeness, reliability, suitability or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this information and the reliance of the information contained herein is at your own risk.  _____Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: How to Set up Manufacturing for Biotech StartupsAccelerating the path to clinical filing applications with rapid toxicology material deliveryLarge molecule manufacturing: addressing challenges with strategies for success

Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on alleviating symptoms but on modifying the course of the disease itself. Their hope is to be able to stop and even reverseneurodegenerative diseases like Parkinsons, and they have the backing of significant players, such as the Michael J Fox Foundation, to do just that.This week I spoke to Antti Vuolanto, CEO of Herantis Pharma, about the work his company is doing, the science behind their approach, and the advantages and challenges of working in biotech in the Nordics.01:10               Meet Antti Vuolanto05:10               The biotech landscape in the Nordics07:07               Herantis Pharma and its mission09:38               Treating symptoms versus disease modification13:31               Herantis in relation to other Parkinson's disease companies15:47               HER-09626:24               The global burden of Parkinson's disease and the unmet need28:56               The role of patient and advocacy groups30:11               The future of Parkinson's disease treatment31:52               How the Nordics can develop and expand their biotech sector36:33               Stay up to date on Herantis and their workInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Finland: Pushing biotech forward in the land of a thousand lakesParkinson's disease: biotech's pursuit for more therapies The stem cell race for Parkinson's disease: Recent studies show significant promise

We're so excited to share this riveting dive into the magic and mystery of tarot with tarot expert Beth Owl's Daughter. In this episode we discuss the spirit of tarot, court cards, reversals, and the ethics of doing readings plus how to know when you're ready to start doing your own readings. For more information on Beth and her work, check out owlsdaughter.comTo sign up for her newsletter (featuring Card of the Week every Monday, plus other tidbits): https://www.owlsdaughter.com/stay-in-touch/#newsletterTo schedule a personal reading: https://www.tickettailor.com/events/bethowlsdaughter/1726070To join her free monthly online Tarot study & friendship group (all levels welcome): https://app.groups.place/group/triangletarotFor her Card of the Week: https://www.owlsdaughter.com/weekly-tarotFind Beth's Blog articles featuring seasonal lore, etc.: https://www.owlsdaughter.com/blogFor more information on us, check out our websites: debbowen.com and samanthafey.com.You can also find Samantha on Instagram @samanthaofey.    If you want to pre-order Deb's book, go to debbowen.com or (if outside the US), check out clairegelder.com  Signed copies of Samantha's book Heavenly Alliance and The Awake Dreamer are available at samanthafey.com.  Be sure to check out Samantha's other podcast Enlightened Empaths.    Have a great week. Be the Light!  

RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions?Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable platform. Founded in 2002, the company today has five different RNAi therapies on the market and a pipeline that continues to expand. While their early focus was on rare disease, today they are expanding into more common conditions, partnering with top pharma companies to bring next-generation therapies to market.This week I sat down with Paul Nioi, Senior Vice President of Research at Alnylam. Paul has more than 20 year's experience in biotech and biopharma, and he walked me through Alnylam's mission and place in the biotech ecosystem, the science of RNAi, the early success treating metabolic disease, and exactly where their platform is expanding into now and in the near future. Paul explains the capacity of RNAi to address neurological and infectious disease, the value of large-scale genomic initiatives, and how he sees drug discovery evolving in the years ahead.01:29               Meet Paul Nioi08:56               Alnylam, its mission, and its science14:35               Two types of partnerships: top pharma, and genomic initiatives22:34               RNAi therapies on the market for rare disease27:29               Expanding into more common conditions32:17               INHBE mutations and cardiometabolic disease35:01               Working with Roche to target hypertension38:58               Looking forward: Alnylam's platform in the near future41:49               What role for national genomic initiatives?45:16               RNAi's place in a future of precision medicineInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeuticsSix biotech companies leading the charge in hemophilia treatmentEpisode 159: Day One DNA - How and why the UK is betting on whole genome sequencing for every newborn

Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is depressive disorder, commonly called depression, with some 280 million people suffering from either mild, moderate or severe depression.Conventional treatments for depression such as selective serotonin reuptake inhibitors, or SSRIs, can work for many people but for some suffering from treatment resistant depression, options can be limited, but some new therapies are in the clinic and might offer some hope. Beckley PsyTech is a UK biotech that is working with next-generation psychedelic-based compounds administered in a short clinic visit once every two months. With positive results from their recent Phase 2B study and a partnership with atai Life Sciences, Beckley believes they are on their way to redefining how depression is treated.01:38               Meet Cosmo Feilding03:04               Beckley PsyTech, its mission and its focus08:36               BPL-003 and next generation psychedelics11:16               Intranasal delivery and its advantages14:26               Psychedelics in the clinic and Phase IIb trial results18:32               Safety: suicide signals and adverse events21:02               Applications for psychedelics outside of depression24:11               The global economic costs of mental health disorders27:40               Comparing Beckley PsyTech to Compass Pathways and GH Research35:26               Regulatory hurdles and the stigma around psychedelics38:14               Partnering with atai Life Sciences and the future of Beckley PsyTech43:16               Milestones ahead for Beckley PsyTech45:44               A future vision for patients suffering from depressionInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: New antidepressants: tackling treatment resistant depressionPsychedelics sans side effects: neuroplastogens gain groundFrom LSD to healing minds: Where are we standing in psychedelic drug development?

The UK is preparing to change the game for healthcare - but why, how, and what will it cost?Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country's 10 Year Health Plan, the program aims to identify rare genetic diseases early, prevent harms from delayed treatment and reduce future healthcare costs for the NHS. Yet along with those potential upsides come a range of ethical and practical questions, too: who guards the sequenced data, who can access it, how can consent be informed, managed and withdrawn years later, and what is the best way to gather the genetic material required to fully sequence the DNA of 700,000 infants each year?This week, I spoke to Neil Ward of PacBio to understand more about this program, compare it to other national genome sequencing programs in Europe and Asia, and discuss the promise of unlocking the ‘language of life'.02:02               Meet Neil Ward09:10               PacBio, its mission, and its current focus17:13               The UK national newborn gene sequencing effort21:20               Ethical and practical challenges for national newborn sequencing24:34               Short-read versus long-read sequencing30:48               Dried blood spots versus cord blood35:57               Lessons for the UK from Thailand38:58               Trends in national newborn screening programs worldwide41:46               What parents and policymakers must know45:20               Exciting things in the genomics space on the horizonThis episode is brought to you by MedChemExpress.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: The past, present, and future of genome sequencingThe next frontier in genomic technologies for rare diseasesSeven genome sequencing companies to look out for

Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too?Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, and – somewhat obviously – the slaughter of hundreds of millions of animals every year. Cultivated meat – that is meat that is grown in a lab – requires little land, less energy, and in the case of Meatly, nothing more than a single cell from a single chicken egg, once. This week I sat down with Owen Ensor, CEO of UK biotech startup Meatly, to talk all things cultivated meat. He explains the science behind his company's cultivated meat process, the significant cost savings that Meatly has made to bring down prices for their product, and how his company became the very first in Europe to have a cultivated meat product approved for sale, in the hands of consumers, and in the bellies of beloved cats and dogs.01:29               Meet Owen Ensor05:10               Meatly and its mission10:12               The science of cultivated meat19:41               Common criticisms of cultivated meat25:33               Regulation, and geographical diversity in regulation32:24               Looking forward: from pets to human consumption?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Cultured Meat Is Coming Soon: Here's What You Need to Know10 cultured meat companies driving sustainable food in 2025The future of food: what's behind the cell-cultured meat industry regulations?

With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined by Alison Pritchard, Vice President, Business Development at Cryoport Systems, to learn more about how they support life science innovators worldwide.Cryoport Systems evolved alongside the life science  industry and expanded its capabilities into full-scale supply chain management solutions that support the critical journeys of the biopharmaceutical, reproductive medicine, and animal health markets.In this episode we look at the ATMP market, the regulatory landscape in EMEA, and the importance of supply chain resilience for cutting edge therapies, whether from established pharmaceutical companies or emerging biotechs and startups.00:02:14   The state of the ATMP market in 202500:07:20    Regulatory trends in EMEA00:13:53    Operational and supply chain challenges00:22:13    Lessons in supply chain resilience00:28:56   Outsourcing trends in biotech00:37:34    Geopolitical influences on the ATMP supply chain00:40:39    Cryoport Systems' plans for the future00:45:53    Final wordInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Cracking the code: Delivering biotherapeutics successfully across EMEAUnlocking consistency in ATMP development: How cryopreservation strengthens Europe's cell therapy supply chain

Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge.This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, about his company's first-in-class approach to fighting inflammation, and what the future might hold for his “pipeline in a product”.01:26   Introducing Niels Riedemann04:28   InflaRx and its mission06:37   The competitive landscape in anti-inflammatory therapeutics07:21   The market for anti-inflammatories08:40   The challenge of taking a drug from R&D to commercialization11:06   The science behind the C5a and C5aR approach14:37   Why is InflaRx the first to focus on these selective inhibitors?19:18   The importance of the MAC formation21:05   InflaRx and its disease targets25:46   Applications beyond anti-inflammatories27:50   Lessons learned from the clinic29:54   Growth forecasts for InflaRx31:48   Different approaches to addressing inflammation33:51   The role of academia in breakthrough therapies36:11   Beyond Europe and North America, addressing the global demand for therapeuticsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Why is the immunology and inflammation market suddenly attracting a wave of investment?Let's Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to TreatJAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?

Blaine begins the episode with a podcast overview and the generalities of this week's episode (0:02). Once Donovan joins, they discuss the return of the longest-running TV show, 'It's Always Sunny In Philadephia' and determine how its sustained its longevity (3:15). From there, they have brief discussion on the Apple TV+ series 'Stick' and its most recent episode (11:14). To conclude the non-spoiler segment, they give thought to 'The Bear' as a whole season (14:42). After a short break, it's time to discuss the ridiculous plot points of both 'It's Always Sunny In Philadelphia' and 'Abbott Elementary,' as the gang end their time there (14:57). Both hosts agree that the Apple TV+ 'Stick' had its best episode thus far, and they explain why (32:38). Finally, it's the last four episodes of the fourth season of 'The Bear' (35:38) Was it better than season three? Were problems solved? All that, and more on this week's Taking It Down episode. For more, visit the link that's provided here to go to The Alabama Take: https://thealabamatake.com/If you wish to sign up for the newsletter mentioned, use this link to sign up and have it delivered to your inbox: https://thealabamatake.com/newsletterTo help the podcast and The Alabama Take website, visit the link here: https://buymeacoffee.com/thealabamatake

Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes.  OMass's MC2 program targeting Congenital Adrenal Hyperplasia, or CAH, is set to enter the clinic this year and in our interview today she walks me through how the company is preparing for their trials, how their approach differs to existing treatment options, and the impact on patient lives they hope to have. A leader in the UK biopharma industry, she also explains the strengths of the UK industry and how it can maintain an edge in the face of competition from Europe and the US.01:07   Meet Ros Deegan02:36   Cambridge and INSEAD04:24   Building industry experience05:16   Biotech in the US vs Biotech in the UK06:19   OMass: mission and ambition07:16   Funding the mission08:18   The importance of partnerships09:17   Industry and government10:37   OMass and CAH13:11   The differentiator for patient outcomes14:49   Into the clinic in 202516:31   CAH patients and patient groups19:29   The importance of hiring the right people20:55   The Oxford ‘brand' in biotechnology22:17   Preparing for the clinic23:43   Regulation and manufacturing26:17   Partnering with top pharma27:35   The importance of building value28:41   How the UK can compete on a global scale30:39   What's next for OMass32:59   The future of targeting rare diseaseInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 biotech companies making a difference in rare diseasesRare Disease Day: seven drugs awaiting approval in 2025

The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. Chronic lower back pain – where the pain persists for more than 3 months – develops in between 5 and 10% of all lower back pain cases, with life-altering impacts for patients.And that's where today's guest, Steve Ruston, of Persica Pharmaceuticals comes in. Persica is developing a groundbreaking and transformative treatment for chronic Low Back Pain. Persica is targeting the cause of chronic lower back pain: the underlying bacterial infection. Unlike conventional approaches that manage symptoms, Persica's drug enables the infection to clear, reducing inflammation, pain and disability at the source.1:20     Introducing Steve Ruston of Persica Pharmaceuticals3:53     Lessons learnt from developing blockbuster drugs6:35     Global experiences in the biopharma industry8:32     Persica Pharmaceuticals and its mission10:26   Collaborations with a network of partners11:48   A non-opioid approach to addressing lower back pain13:35   Treating the cause, not the symptoms15:05   How Persica's treatment work18:59   Practical impacts of Persica's treatment21:07   Identifying patients for cLBP treatment23:24   How Persica is changing the treatment landscape28:10   Regulatory hurdles to overcome34:37   Securing funding for Persica's innovation36:16   The future of treating painInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?Developing non-opioid pain drugsRedefining chronic pain treatment

Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte.Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions.This week I had the chance to speak to Humacyte founder, President and Chief Executive Laura Niklason about the company she has built, the science she is driving forward, and the real-world applications for Humacyte's lab-grown blood vessels in some of the most devastating and dangerous conflicts.1:00     Introducing Laura Niklason4:50     Humacyte and its mission6:27     Competitive landscape7:45     Partnering for scale9:49     How to grow blood vessels in the lab11:47   Implanting the vessels13:32   Human vessels vs synthetic vessels15:10   The manufacturing process16:23   Overcoming skepticism, demonstrating value19:01   Navigating the regulatory approval process21:17   The role of the Department of Defense in innovative biotech22:30   Using Humacyte vessels in the field23:20   Humacyte vessels in the Ukraine War28:22   Lessons from the Ukraine War30:09   Goals for the coming years33:35   Scaling manufacturingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic:Current trends & innovations in 3D organoidsThe future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells

What are the most interesting questions in biotech, and is it even possible to find answers to those questions?Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, 'Some questions about biotech that I find interesting' provoked conversations online as readers engaged with questions about topics as diverse as the impacts of regulation, the role of serendipity in drug discovery, clinical trial failure rates, and the best structure for governing large pharmaceutical companies companies.In this episode Alex explains the work he is doing at Convoke before opening the door to his insatiable curiosity about the biotech industry.01:17               Introducing Alex Telford04:28              The business of biotech09:02              Convoke and its mission14:21               ‘Some questions about biotech that I find interesting'16:57               Why founders should be writing and blogging18:44               Generating good questions about biotech20:50              AI and its role in drug discovery26:21               Will AI mean the end of serendipitous drug discovery?28:15               Regulatory challenges for biotech34:17               Is the FDA a net positive or net negative for the industry?36:56              The unanswerable questions in biotech39:00              Digital twins in biotechnology42:15               The next interesting questions in biotechInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 12 AI drug discovery companies you should know aboutDoes the FDA need to tighten its grip on drug trials in the U.S.?2025 predictions: Which trends are set to shape the biotech industry this year?

We hope you've enjoyed this journey of the first season of The Karen Kingsbury Show! Today's episode is the final episode and a very special one as Karen talks with Tyler Russell about his very serious decision to co-write and direct Someone Like You. Tyler shares the moment when he knew, there was no turning back!Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!SHOW LINKS:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Someone Like You is out in theaters! Over this past season you've gone through the journey of Karen's life and how it's come to producing her very own movie! Now you can catch that movie on the big screen! On today's episode Karen talks with the stars of Someone Like You, Jake Allyn and Sarah Fisher, and listen closely, because Karen may even share a secret!Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares. Thanks for listening and sharing this episode with a friend! SHOW LINKS:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Karen shares the deeply personal moment when her husband suggested they sell everything ... if that's what it took to follow God's will.Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! SHOW LINKS:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Welcome back to another great episode of The Saren Kingsbury Show. On today's show, Karen talks with Tay Lautner about their Lemons Foundation and the importance of mental health. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Lemons by TaySqueeze Podcast Connect with Tay Lautner Suicide Hotline Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

On today's show Karen Kingsbury talks with her dear friend Shelene Bryan about finding a reason to laugh. Whether you're on a cruise or in a prison, Shelene reminds all of us there's laughter everywhere!  Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.  Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

In Episode 11 of The Karen Kingsbury Show, Karen talks with her daughter Kelsey about one of the mottos their family lives by: look for the miracles in life. From an officer that may have been an angel, to Rod Stewart and the High Line Park, Kelsey and Karen share the many memories they have of witnessing miracles. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

The mother daughter dynamic is so beautiful, and yet every mother and daughter knows that it can also be complex. On today's show Karen and her daughter Kelsey join friends and mother daughter duo Candace and Natasha Bure to talk about this relationship. Cameron and Karen share their experience of raising strong daughters and Natasha and Kelsey share what it was like growing up with parents in the spotlight. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Welcome back to another great episode of The Karen Kingsbury Show. We have such a treat for you today as Karen is joined by her daughter Kelsey, and her son-in-love, Kyle. Kelsey and Kyle open up and share their sweet love story and the way God brought their lives together. Little did Kyle and Kelsey know, this love story was the fruition of prayers prayed between Karen and Donald years earlier. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! Come back next week!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.Check out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

It was a beautiful evening as the kids watched a movie and Donald played his guitar by the fireplace. But suddenly, his arm began to tingle and he lost all ability to move or speak. 911 was called and immediately paramedics filled the living room. That's when Karen was told, "ma'am, your husband is having a stroke." On today's show, Donald and Karen relive that moment. You'll hear about the peace they experienced, the multiple miracles they witnessed, and the legacy they hope to leave. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! Come back next week!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

He had the intuition that only a father could. He was his daughter's biggest fan and encouraged her to write what was in her heart; however, as he neared the end of his life, he simply couldn't remember she was an author. On today's show Karen and her husband Donald remember her late father and the pivotal role he played in both of their lives. There's no manual to being a good father, but Donald gives practical advice to steer every parent in the right direction.  Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! Come back next week!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you. Check out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

After having having several children, Karen and her husband Donald just knew they had more love to share. As God led them down the road of adoption, what they thought would be one child through domestic adoption, turned into a story only God could have written. In today's episode Karen and Donald share their experience with international adoption, the challenges they faced, funny memories, and how God took a broken story and made something beautiful!Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! Come back next week!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you. Check out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

It's a family that all began on an airplane home, and it's the family you all came to know and love, The Baxter Family. On today's show Karen sits down with Scott and Missy Reeves and reminisces on The Baxter family journey and how it changed the lives of so many.  Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! Come back next week!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you. Check out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

"Please come back to me.... please come back to me." Karen whispered these words as she handed her 3-weeks-old son over to the heart surgeon. On today's episode Karen, with her son Austin, share a deeply personal and vulnerable story of Austin being born with a heart defect. If you've ever experienced the sudden loss of a dream, and are in need of a reminder that God loves his children and is trustworthy, this episode is for you! Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! Come back next week!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you. Check out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

This week: Jen answers questions from Patreon subscribers about: her second tattoo, being on a TV game show, writing for TV, how to be in a relationship with an ADHD-er and more! Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxTo listen to Q&A WITH JK PART 1 go here: https://tinyurl.com/dnjfuwwk Learn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about the right way to put sprinkles on ice cream, the night she and Winona Ryder hung out, Jen's parents want to party with her friends, killing spotted lantern flies in NYC, AI therapists are not helpful, and the Godfather of AI quit his job at Google to warn the world about killer robots.Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about a very chatty customer service phone operator for Jet Blue, being afraid of the woods at night, debunking government conspiracy alien craft crash theories, and the Next Door app'ers are freaking out over a creepy van in the neighborhood.Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about the excitement of the SAG-AFTRA Union joining the WGA on strike, Jen's parents are pro Matt Damon and anti-billionaire, the downfall of Jonah Hill as a mental health role model, Jen is worried that Madonna is secretly on drugs, and an apology for suggesting going to Target on a first date. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

SEASON 11: EPISODE 26: SHIPSRELEASE DATE 7/13/2023This week: Jen reads a thread on the Next Door app about a couple who were appalled that teenaged boys threw eggs at them. Jen goes to a crappy Titanic exhibit in NYC, the problem with billionaires and dangerous expeditions, and Elon wants childless people to lose the right to vote. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen is very scattered but manages to talk about her addiction and then crash watching Married At First Sight when she was sick for a week, great advice on the futility of time management from a book Jen read, a heart-warming ADHD tale of my bonding with a stranger, and there's more drama happening on the Next Door App! Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about whistleblower David Grush testifying that there is a secret government committee that has recovered “non-human” spacecraft, nobody is afraid of aliens, the Gen-Z trend of “bed-rotting” which Jen calls “Bedquarters”, a Rona rebound, someone on the Next Door App wants to sue Jen for slander and more! Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: patreon.com/jenkirkmanLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about Kim Cattrall's upcoming cameo on “And Just Like That” and the annoying line from Carrie in the trailer about using the stove for shoes. Also Jen talks about getting the Coco after 3 1/2 years of outrunning it, Al Pacino and Robert DeNiro are insane for having kids at age 80, and Jen continues to troll people on the Next Door App. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: patreon.com/jenkirkmanLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen reads and gives her commentary on Jack Smith's indictment of Donald Trump for having boxes of classified info at Mar-A-Lago, Seth Rogan is a child-free hero, not having kids isn't interesting to talk about - why do people care, the time Francis Bean Cobain told Jen she liked her comedy, Jen's parents won't make a will, and what “Women are Literally Humans” means. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: patreon.com/jenkirkmanLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Read Jack Smith's Trump Indictment Pages here: https://tinyurl.com/4kr6kfxwGet “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jen talks about how her podiatrist thought Jen was upset because she is “old”, making new friends as an adult, coping with a fear of building heights and elevators with Klonopin and oversharing, watching The Notebook for the first time last week and more random ADHD rambling! Go to Patreon to hear this episode in it's entirety (60-90 minutes) and without ads: patreon.com/jenkirkmanTo shop Jen's merchandise store go here: http://jenkirkman.merchcentral.comTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.